Latest news articles

Added 2 months ago Drug news

Data Safety Monitoring Board positive recommendation for RESOLVE-IT Phase III trial of elafibranor to proced for NASH.- Genfit.

GENFIT announced that the Data Safety Monitoring Board (DSMB) issued a new positive recommendation for the continuation of the RESOLVE-IT...

Added 3 months ago Drug news

Norgine reports rifaximin study shows improved outcomes on the waiting list with a significant reduction in all cause hospital admissions and episodes of sepsis.- Norgine +

Norgine B.V. highlighted new data from a UK retrospective study showing that rifaximin-a prescribed for the recurrence of overt hepatic...

Search all news articles for Hepatitis
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Transplantation

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Cystic Fibrosis Knowledge Centre

Cystic Fibrosis Knowledge Centre

View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.

Load more

Guidelines

EASL Clinical Practice Guidelines on hepatitis E virus infection

Infection with hepatitis E virus (HEV) is a significant cause of morbidity and mortality, representing an important global health problem. Our understanding of HEV has changed completely over the past decade.

Added 1 month ago

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis

The following Clinical Practice Guidelines (CPGs) represent the first CPGs on the management of decompensated cirrhosis.

Added 1 month ago

EASL Recommendations on Treatment of Hepatitis C 2018

These European Association for the Study of the Liver Recommendations on Treatment of Hepatitis C describe the optimal management of patients with acute and chronic HCV infections in 2018 and onwards.

Added 1 month ago

Search all guidelines for Hepatitis
 

Journal articles

Discovery and preclinical development of dasabuvir for the treatment of hepatitis C infection.

Introduction: Hepatitis C virus (HCV) is a leading cause of liver-related morbidity and mortality. Positively, the introduction of new directly-acting antivirals (DAAs) have led to dramatic...

Added 9 months ago

Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C.

Introduction: The advent of direct-acting antiviral (DAA) treatments for chronic hepatitis C virus (HCV) infection has dramatically increased rates of cure. However, there remain difficult-to-treat populations...

Added 9 months ago

Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C.

Introduction: The fixed-dose combination of three direct-acting antivirals (DAA), namely sofosbuvir, velpatasvir and voxilaprevir is the first pangenotypic, single tablet regimen developed for the treatment of HCV infection.

Added 9 months ago

Search all journal articles for Hepatitis
 

Clinical trials

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) (RESOLVE-IT)

The primary objectives of this study are to evaluate the effect of elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with NASH and fibrosis.

Added 9 months ago

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITION-1)

The purpose of this study is to assess the safety and efficacy of ABT-493/ABT-530 following 12 weeks of treatment in adults with chronic Hepatitis C Virus Infection genotype 1, 2, 4, 5 or 6 infection and compensated cirrhosis.

Added 10 months ago

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor

This study will evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) for 12 weeks and of sofosbuvir/velpatasvir (SOF/VEL) FDC for 12 weeks...

Added 9 months ago

Search all clinical trials for Hepatitis
 
Alex Keen

Alex studied Biological Sciences at university before joining EPG Health in January 2017, where he works as a digital content manager and editor.

In his spare time, Alex enjoys relaxing with a cool pint in the company of good friends. 

ILC 2018 – Targetable pathways in liver disease: from identification to clinical application

A number of studies from the speakers at this year's ILC Basic Science Seminar are discussed here, focusing on targetable pathways in liver disease, covering pathway identification, potential drug targets and their clinical application.

CME

Abnormal liver function tests: case-based discussion

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
0
Registration required
1
Subscription fee
0

Abnormal liver function tests: a guide to interpretation

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
90

Ascites: an unusual case: in association with Gut

Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
60
Search all CME for Hepatitis